Trial Profile
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jul 2022
Price :
$35
*
At a glance
- Drugs INCB 52793 (Primary) ; Itacitinib (Primary) ; Parsaclisib (Primary) ; Azacitidine; Bortezomib; Bortezomib; Carfilzomib; Dexamethasone; Gemcitabine; Lenalidomide; Paclitaxel; Pomalidomide
- Indications Acute myeloid leukaemia; Adenocarcinoma; Advanced breast cancer; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Haematological malignancies; Hodgkin's disease; Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Pancreatic cancer; Solid tumours; Triple negative breast cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Incyte Corporation
- 01 Jul 2022 Results published in the Clinical Lymphoma, Myeloma & Leukemia
- 06 Apr 2020 Status changed from completed to discontinued.
- 04 Sep 2019 Status changed from active, no longer recruiting to completed.